Radiation oncology firm Accuray has received the CE Mark for its Radixact treatment delivery platform.
The package includes Accuray's Precision treatment planning system and its iDMS data management system. The platform increases the treatment speed and ease of use of Accuray's TomoTherapy device, the company said.
Radixact received clearance from the U.S. Food and Drug Administration (FDA) in June, according to the firm.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
